Literature DB >> 24418051

Altered skin flowmotion in hypertensive humans.

R S Bruning1, W L Kenney1, L M Alexander2.   

Abstract

Essential hypertensive humans exhibit attenuated cutaneous nitric oxide (NO)-dependent vasodilation. Using spectral analysis (fast Fourier transformation) we aimed to characterize the skin flowmotion contained in the laser-Doppler flowmetry recordings during local heating-induced vasodilation before and after concurrent pharmacological inhibition of nitric oxide synthase (NOS) in hypertensive and age-matched normotensive men and women. We hypothesized that hypertensive subjects would have lower total power spectral densities (PSDs), specifically in the frequency intervals associated with intrinsic endothelial and neurogenic control of the microvasculature. Furthermore, we hypothesized that NOS inhibition would attenuate the endothelial frequency interval. Laser-Doppler flowmetry recordings during local heating experiments from 18 hypertensive (MAP: 108±2mmHg) and 18 normotensive (MAP: 88±2mmHg) men and women were analyzed. Within site NO-dependent vasodilation was assessed by perfusion of a non-specific NOS inhibitor (N(G)-nitro-l-arginine methyl ester; l-NAME) through intradermal microdialysis during the heating-induced plateau in skin blood flow. Local heating-induced vasodilation increased total PSD for all frequency intervals (all p<0.001). Hypertensives had a lower total PSD (p=0.03) and absolute neurogenic frequency intervals (p<0.01) compared to the normotensives. When normalized as a percentage of total PSD, hypertensives had reduced neurogenic (p<0.001) and augmented myogenic contributions (p=0.04) to the total spectrum. NOS inhibition decreased total PSD (p<0.001) for both groups, but hypertensives exhibited lower absolute endothelial (p<0.01), neurogenic (p<0.05), and total PSD (p<0.001) frequency intervals compared to normotensives. These data suggest that essential hypertension results in altered neurogenic and NOS-dependent control of skin flowmotion and support the use of spectral analysis as a non-invasive technique to study vasoreactivity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24418051      PMCID: PMC5466804          DOI: 10.1016/j.mvr.2014.01.001

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  45 in total

1.  Involvement of sympathetic nerve activity in skin blood flow oscillations in humans.

Authors:  Torbjörn Söderström; Aneta Stefanovska; Mitja Veber; Henry Svensson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05       Impact factor: 4.733

2.  Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans.

Authors:  Caroline J Smith; Lakshmi Santhanam; Rebecca S Bruning; Anna Stanhewicz; Dan E Berkowitz; Lacy A Holowatz
Journal:  Hypertension       Date:  2011-09-19       Impact factor: 10.190

3.  Neurogenic and myogenic resting skin blood flowmotion in subjects with masked hypertension.

Authors:  B Gryglewska; M Necki; M Cwynar; T Baron; T Grodzicki
Journal:  J Physiol Pharmacol       Date:  2010-10       Impact factor: 3.011

4.  Blunted post-ischemic increase of the endothelial skin blood flowmotion component as early sign of endothelial dysfunction in chronic kidney disease patients.

Authors:  Marco Rossi; Adamasco Cupisti; Cinzia Di Maria; Fabio Galetta; Giuliano Barsotti; Gino Santoro
Journal:  Microvasc Res       Date:  2007-08-24       Impact factor: 3.514

5.  Contributions of endothelial nitric oxide synthase, noradrenaline, and neuropeptide Y to local warming-induced cutaneous vasodilatation in men.

Authors:  Gary J Hodges; Paul A Sparks
Journal:  Microvasc Res       Date:  2013-09-06       Impact factor: 3.514

6.  Generalised wavelet analysis of cutaneous flowmotion during post-occlusive reactive hyperaemia in patients with peripheral arterial obstructive disease.

Authors:  M Rossi; S Bertuglia; M Varanini; A Giusti; G Santoro; A Carpi
Journal:  Biomed Pharmacother       Date:  2005-06       Impact factor: 6.529

7.  Oral atorvastatin therapy increases nitric oxide-dependent cutaneous vasodilation in humans by decreasing ascorbate-sensitive oxidants.

Authors:  Lacy A Holowatz; W Larry Kenney
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-06-29       Impact factor: 3.619

8.  Absent post-ischemic increase of blood flowmotion in the cutaneous microcirculation of healthy chronic cigarette smokers.

Authors:  M Rossi; A Carpi; C Di Maria; F Galetta; G Santoro
Journal:  Clin Hemorheol Microcirc       Date:  2007       Impact factor: 2.375

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Rhythmic contractions of isolated small arteries from rat: influence of the endothelium.

Authors:  H Gustafsson; M J Mulvany; H Nilsson
Journal:  Acta Physiol Scand       Date:  1993-06
View more
  10 in total

1.  Sensory nerve-mediated and nitric oxide-dependent cutaneous vasodilation in normotensive and prehypertensive non-Hispanic blacks and whites.

Authors:  Brett J Wong; Casey G Turner; James T Miller; Demetria C Walker; Yesser Sebeh; Matthew J Hayat; Jeffrey S Otis; Arshed A Quyyumi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-06-19       Impact factor: 4.733

2.  Effect of skin temperature on cutaneous vasodilator response to the β-adrenergic agonist isoproterenol.

Authors:  Gary J Hodges; Dean L Kellogg; John M Johnson
Journal:  J Appl Physiol (1985)       Date:  2015-02-19

3.  Impaired Hydrogen Sulfide-Mediated Vasodilation Contributes to Microvascular Endothelial Dysfunction in Hypertensive Adults.

Authors:  Jody L Greaney; Jessica L Kutz; Sean W Shank; Sandeep Jandu; Lakshmi Santhanam; Lacy M Alexander
Journal:  Hypertension       Date:  2017-03-27       Impact factor: 10.190

4.  Diurnal variations and pulpal status: is there a need for FFT besides LDF?

Authors:  Herman J J Roeykens; Roeland J G De Moor
Journal:  Lasers Med Sci       Date:  2018-06-13       Impact factor: 3.161

5.  Hydrogen sulfide-dependent microvascular vasodilation is improved following chronic sulfhydryl-donating antihypertensive pharmacotherapy in adults with hypertension.

Authors:  Gabrielle A Dillon; Anna E Stanhewicz; Corinna Serviente; Jody L Greaney; Lacy M Alexander
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-09-03       Impact factor: 5.125

Review 6.  Current concepts of active vasodilation in human skin.

Authors:  Brett J Wong; Casey G Hollowed
Journal:  Temperature (Austin)       Date:  2016-06-21

7.  The Venoarteriolar Reflex Significantly Reduces Contralateral Perfusion as Part of the Lower Limb Circulatory Homeostasis in vivo.

Authors:  Henrique Silva; Hugo A Ferreira; Hugo P da Silva; L Monteiro Rodrigues
Journal:  Front Physiol       Date:  2018-08-17       Impact factor: 4.566

8.  Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis.

Authors:  Geraldine F Clough; Andrew J Chipperfield; Marjola Thanaj; Eleonora Scorletti; Philip C Calder; Christopher D Byrne
Journal:  Front Physiol       Date:  2020-06-03       Impact factor: 4.566

Review 9.  Historical reviews of the assessment of human cardiovascular function: interrogation and understanding of the control of skin blood flow.

Authors:  David A Low; Helen Jones; N Tim Cable; Lacy M Alexander; W Larry Kenney
Journal:  Eur J Appl Physiol       Date:  2019-11-27       Impact factor: 3.078

Review 10.  Vascular Health Triad in Humans With Hypertension-Not the Usual Suspects.

Authors:  Sushant M Ranadive; Gabrielle A Dillon; Sara E Mascone; Lacy M Alexander
Journal:  Front Physiol       Date:  2021-10-01       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.